Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells

Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory. Valproic acid (VPA) has emerged as an anticancer drug via inhibition of histone deacetylases (HDACs), but the therapeutic advantages of a combination with V...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ryu, Chung Heon, Yoon, Wan Soo, Park, Kwang Ywel, Kim, Seong Muk, Lim, Jung Yeon, Woo, Ji Sun, Jeong, Chang Hyun, Hou, Yun, Jeun, Sin-Soo
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2012
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3373250/
https://ncbi.nlm.nih.gov/pubmed/22701311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/987495
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars